REBLOZYL

all catalysts(0)

nothing on the calendar yet

News(4)

• An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
  In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the pharmaceutical giants.
  biopharma_dive · 8d ago
• Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
  Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.
  biopharma_dive · 11d ago
• BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
  Strong quarterly results are prompting Bristol Myers Squibb to lift its 2026 outlook, though the company is facing another delay for key Cobenfy Alzheimer’s data and a pushed-back readout for milve…
  biospace · 12d ago
• Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
  Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.
  biopharma_dive · 3mo ago